03:42 PM EST - Lorus Therapeutics Inc. : announced today that the company will pursue the clinical development of LOR-253, its first-in-class, small molecule inducer of the tumor suppressor Krüppel-like factor 4, in acute myeloid leukemia and other hematologic malignancies. Lorus Therapeutics Inc.
shares T.LOR are trading up $0.015 at $0.31.
